Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM. Children’s Oncology Group’s 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. PubMed PMID: 37505794; PubMed Central PMCID: PMC10660893.
Study ID Citation
Abstract
The goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children’s Oncology Group (COG) trials include: 1) superior event free survival with the addition of brentuximab vedotin (Bv) in frontline regimens for high-risk disease, 2) successful reduction in myeloablative regimens with demonstrated safety and efficacy of Bv and checkpoint inhibitor therapy in relapsed disease, and the 3) potential to select a population who can be salvaged after relapse without receiving a stem cell transplant. The COG HL committee will lead an NCTN phase 3 trial to evaluate the combination of Bv/Nivolumab in early-stage disease. Ongoing advances in technology, and blood biomarkers are increasing the ability to deliver biologically driven, personalized treatment for HL.